These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Normal human immunoglobulins for intravenous use (IVIg) delay hyperacute xenograft rejection through F(ab')2-mediated anti-complement activity. Latremouille C, Genevaz D, Hu MC, Schussler O, Goussef N, Mandet C, Bruneval P, Haeffner-Cavaillon N, Carpentier A, Glotz D. Clin Exp Immunol; 1997 Oct; 110(1):122-6. PubMed ID: 9353158 [Abstract] [Full Text] [Related]
45. [Xenogeneic hyperacute rejection of the lung in rats]. Tavakoli R, Devaux JY, Nonnenmacher L, Louvel A, Houssin D. Chirurgie; 1990 Oct; 116(8-9):684-9. PubMed ID: 2129985 [Abstract] [Full Text] [Related]
46. The effect of total blood exchange with PHP solution on cardiac xenotransplantation. Liu H, Agishi T, Suga H, Hayasaka Y, Teraoka S, Ota K. Artif Organs; 1995 Apr; 19(4):324-7. PubMed ID: 7598651 [Abstract] [Full Text] [Related]
48. Proceedings: Modification of the hyperacute reaction in the rat by sulphinpyrazone. Jamieson SW. Thromb Diath Haemorrh; 1975 Sep 30; 34(1):348-9. PubMed ID: 1103359 [No Abstract] [Full Text] [Related]
49. Allogeneic heart transplantation following xenogeneic bridging. Schütz A, Pratschke J, Breuer M, Hammer C, Engelhardt M, Brandl U, Babic R, Reichart B, Kemkes BM. Transpl Int; 1992 Sep 30; 5 Suppl 1():S307-10. PubMed ID: 14621808 [Abstract] [Full Text] [Related]
50. [A new model of isolated perfused heart. Study of hypodermin A in hyperacute xenograft rejection]. Régimbeau JM, Malassagne B, Taboit F, Boulard C, Houssin D, Weill B. Ann Chir; 2001 Dec 30; 126(10):1007-15. PubMed ID: 11803623 [Abstract] [Full Text] [Related]
53. Reversibility of graft rejection following a short cyclosporin-A administration 5 days after grafting. Mazzoni G, Mazzoni P. Microsurgery; 1986 Dec 30; 7(3):114-6. PubMed ID: 3534511 [Abstract] [Full Text] [Related]
54. Organ xenografting between rodents: an evolutionary perspective. Chaline J, Cardoso J, Houssin D. Transpl Int; 1994 May 30; 7(3):216-22. PubMed ID: 8060472 [Abstract] [Full Text] [Related]
55. Xenografts. Review of the literature and current status. Council on Scientific Affairs. JAMA; 1985 Dec 20; 254(23):3353-7. PubMed ID: 3906159 [Abstract] [Full Text] [Related]
56. [Experimental xenografting in widely divergent species. Modification of the hyperacute rejection by pretreatment of dogs (recipient) with soluble liver antigens from pigs (donors)]. Land W, Hammer C, Fiedler L, Brendel W. Res Exp Med (Berl); 1972 Dec 20; 158(1):1-22. PubMed ID: 4559679 [No Abstract] [Full Text] [Related]
57. Effectiveness of prostaglandin E1 and procarbazine hydrochloride in prolonging the survival of vascularized cardiac hamster-to-rat xenograft. Kakita A, Blanchard J, Fortner JG. Transplantation; 1975 Dec 20; 20(6):439-42. PubMed ID: 1209725 [Abstract] [Full Text] [Related]
58. Understanding the pathogenesis and the pathology of hyperacute cardiac rejection. Rose AG. Cardiovasc Pathol; 2002 Dec 20; 11(3):171-6. PubMed ID: 12031770 [Abstract] [Full Text] [Related]
59. Eosinophilic droplets similar to red cells are present in the hyperacute rejection of heart xenografts. Beranek JT. J Intern Med; 1997 Jan 20; 241(1):89-90. PubMed ID: 9042099 [No Abstract] [Full Text] [Related]
60. The fate of experimental organ-cultured corneal xenografts. Doughman DJ, Miller GE, Mindrup EA, Harris JE. Transplantation; 1976 Aug 20; 22(2):132-7. PubMed ID: 788244 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]